Full length parathyroid hormone (1–84) in the treatment of osteoporosis in postmenopausal women

References

• AurbachGD1959Isolation of parathyroid hormone after extraction with phenolJ Biol Chem23431798113848891
   PubMed Web of Science ®Google Scholar
• BauerDCGarneroPBilezikianJP2006Short-term changes in bone turnover markers and bone mineral density response to parathyroid hormone in postmenopausal women with osteoporosisJ Clin Endocrinol Metab911370516449339
   PubMed Web of Science ®Google Scholar
• BauerWAubJCAlbrightF1929Studies of calcium phosphorus metabolism: study of bone trabeculae as ready available reserve supply of calciumJ Exp Med4914562
   PubMedGoogle Scholar
• BlackDMBilezikianJPEnsrudKE2005One year of alendronate after one year of parathyroid hormone (1–84) for osteoporosisN Engl J Med3535556516093464
   PubMed Web of Science ®Google Scholar
• BlackDMGreenspanSLEnsrudKE2003The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosisN Engl J Med34912071514500804
   PubMed Web of Science ®Google Scholar
• BogadoCELangTFZanchettaJR2006Longitudinal changes in trabecular and cortical bmd and indices of bone strength assessed by quantitative computed tomography at the hip of postmenopausal osteoporotic women treated with parathyroid hormone (1–84) for 18 monthsJ Bone Miner Res21Suppl 1S296
   Google Scholar
• BogadoCEZanchettaJRMangoA2005Effects of parathyroid hormone 1–84 on cortical and trabecular bone at the hip as assessed by QCT: results at 18 months from the TOP studyJ Bone Miner Res36Suppl 2S22
   Google Scholar
• BoothbyWM1921The parathyroid glands: a review of the literatureEndocrinology540340
   Google Scholar
• BrownEMPollakMSeidmanCE1995Calcium-ion-sensing cell-surface receptorsN Engl J Med333234407791841
   PubMed Web of Science ®Google Scholar
• CollipJB1925The extraction of a parathyroid hormone which will prevent or control parathyroid tetany and which regulates the level of blood calciumJ Biol Chem63395438
   Google Scholar
• DempsterDWCosmanFKurlandES2001Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: a paired biopsy studyJ Bone Miner Res1618465311585349
   PubMed Web of Science ®Google Scholar
• DempsterDWCosmanFParisienM1993Anabolic actions of parathyroid hormone on boneEndocr Rev146907098119233
   PubMed Web of Science ®Google Scholar
• DempsterDWMoreauIAVarelaA2005Treatment of postmenopausal osteoporotic women with parathyroid hormone 1–84 for 18 months improves trabecular bone architecture: a study of iliac crest biopsies using microcomputed tomographyJ Bone Miner Res36suppl 2S98
   Google Scholar
• DivietiPInomataNChapinK2001Receptors for the carboxyl-terminal region of PTH(1–84) are highly expressed in osteocytic cellsEndocrinology1429162511159865
   PubMed Web of Science ®Google Scholar
• [ECHCPD] European Commission Health & Consumer Protection Directorate2006Dissemination of health information and data [online]. Accessed 14 November 2006. URL: http://ec.europa.eu/health/ph_information/dissemination/diseases/musculo_en.htm#rate
   Google Scholar
• EjerstedCAndreassenTTOxlundH1993Human parathyroid hormone (1–34) and (1–84) increase the mechanical strength and thickness of cortical bone in ratsJ Bone Miner Res810971018237479
   PubMed Web of Science ®Google Scholar
• ErdheimJ1906Ueber tetania parathyreoprivaWeiner Klinishe Wachen-schrift1971617
   Google Scholar
• FogelmanIChristiansenCFordhamJ2005Safety and efficacy of PTH (1–84) at 18 and 24 months in women with postmenopausal osteoporosis receiving hormone therapy: results from the POWER studyJ Bone Miner Res36suppl 2S21
   Google Scholar
• FoxJMillerMANewmanMK2007Treatment of skeletally-mature ovariectomized rhesus monkeys with parathyroid hormone 1–84 for 16 months increases bone formation and density and improves trabecular architecture and biomechanical properties at the lumbar spineJ Bone Mineral Res2226073
   PubMed Web of Science ®Google Scholar
• FoxJMillerMAReckerRR2005Treatment of postmenopausal osteoporotic women with parathyroid hormone 1–84 for 18 months increases cancellous bone formation and improves cancellous architecture: A study of iliac crest biopsies using histomorphometry and micro computed tomographyJ Musculoskelet Neuronal Interact5356716340137
   PubMedGoogle Scholar
• GleyE1891Sur la toxicité des urines des chiens thyroidectomisés: contribution à l’étude des fonctions du corps thyroideComptes Rendus de la Société de Biologie33668
   Google Scholar
• GreenspanSLBoneHGMarriottTB2005Preventing the first vertebral fracture in postmenopausal women with low bone mass using PTH (1–84): results from the TOP studyJ Bone Miner Res36suppl 2S56
   Google Scholar
• GreenspanSLBoneHGEttingerMP2007Effect of recombinant human parathyroid hormona (1–84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosisAnn Intern Med1463263917339618
   PubMed Web of Science ®Google Scholar
• HodsmanABFraherLJOstbyeT1993An evaluation of several biochemical markers for bone formation and resorption in a protocol utilizing cyclical parathyroid hormone and calcitonin therapy for osteoporosisJ Clin Invest911138488450043
   PubMed Web of Science ®Google Scholar
• HodsmanABFraherLJWatsonPH1997A randomized controlled trial to compare the efficacy of cyclical parathyroid hormone versus cyclical parathyroid hormone and sequential calcitonin to improve bone mass in postmenopausal women with osteoporosisJ Clin Endocrinol Metab8262089024265
   PubMed Web of Science ®Google Scholar
• HodsmanABHanleyDAEttingerMP2003Efficacy and safety of human parathyroid hormone (1–84) in increasing bone mineral density in postmenopausal osteoporosisJ Clin Endocrinol Metab8852122014602752
   PubMed Web of Science ®Google Scholar
• JeromeCPBurrDBVan BibberT2001Treatment with human parathyroid hormone (1–34) for 18 months increases cancellous bone volume and improves trabecular architecture in ovariectomized cynomolgus monkeys (Macaca fascicularis)Bone28150911182372
   PubMed Web of Science ®Google Scholar
• MacCallumWGVoegtlinC1908On the relation of the parathyroid to calcium metabolism and the nature of tetanyJohns Hopkins Hospital Bulletin19912
   Google Scholar
• MartinKHruskaKGreenwaltA1976Selective uptake of intact parathyroid hormone by the liver: differences between hepatic and renal uptakeJ Clin Invest587818965485
   PubMed Web of Science ®Google Scholar
• MillerPDGreenspanS2005PTH (1–84) prevents vertebral fracture in postmenopausal women with higher fracture risk: results from the TOP studyOsteoporosis Int16S4S32
   Google Scholar
• MisofBMRoschgerPCosmanF2003Effects of intermittent parathyroid hormone administration on bone mineralization density in iliac crest biopsies from patients with osteoporosis: a paired study before and after treatmentJ Clin Endocrinol Metab881150612629098
   PubMed Web of Science ®Google Scholar
• MorleyPWhitfieldJFWillickGE1997Anabolic effects of parathyroid hormone on boneTrends Endocrinol Metab82253118406808
   PubMed Web of Science ®Google Scholar
• MosekildeLSogaardCHDanielsenCC1991The anabolic effects of human parathyroid hormone (hPTH) on rat vertebral body mass are also reflected in the quality of bone, assessed by biomechanical testing: a comparison study between hPTH-(1–34) and hPTH-(1–84)Endocrinology12942182055197
   PubMed Web of Science ®Google Scholar
• MurrayTMRaoLGDivietiP2005Parathyroid hormone secretion and action: evidence for discrete receptors for the carboxyl-terminal region and related biological actions of carboxyl- terminal ligandEndocr Rev267811315689574
   PubMed Web of Science ®Google Scholar
• NeerRMArnaudCDZanchettaJR2001Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosisN Engl J Med34414344111346808
   PubMed Web of Science ®Google Scholar
• [NIH] NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy2001Osteoporosis prevention, diagnosis, and therapyJAMA2857859511176917
   PubMed Web of Science ®Google Scholar
• [NOF] National Osteoporosis Foundation2002America’s bone health: the state of osteoporosis and low bone mass in our nation. 2002 [online]. Accessed on 20 November 2006. URL: http://www.nof.org/advocacy/prevalence/
   Google Scholar
• PodbesekREdouardCMeunierPJ1983Effects of two treatment regimes with synthetic human parathyroid hormone fragment on bone formation and the tissue balance of trabecular bone in greyhoundsEndocrinology112100066822201
   PubMed Web of Science ®Google Scholar
• PottsJTJuppnerH1996Parathyroid hormone: molecular biology and regulationBilezikianJPRaiszLGRodanGAPrinciples of bone biologyNew YorkAcademic Pr32541
   Google Scholar
• [EMEA] European Medicines Agency2006Authorised medicines for human use—Preotact H-659-00-00 product information [online]. Accessed 18 November 2006. URL: http://www.emea.eu.int/human-docs/Humans/EPAR/preotact/preotact.htm
   Google Scholar
• RayNFChanJKThamerM1997Medical expenditures for the treatment of osteoporotic fractures in the United States in 1995: report from the National Osteoporosis FoundationJ Bone Miner Res1224359240722
   PubMed Web of Science ®Google Scholar
• ReckerRRBareSPMillerMA2004Treatment of osteoporotic women with parathyroid hormone 1–84 for 18 months improves cancellous bone formation and structure: a bone biopsy studyJ Bone Miner Res19suppl 1S97
   Google Scholar
• ReeveJHespRWilliamsD1976Anabolic effect of low doses of a fragment of human parathyroid hormone on the skeleton in postmenopausal osteoporosisLancet179681035857447
   PubMed Web of Science ®Google Scholar
• RiggsBLMeltonLJ3rd1995The worldwide problem of osteoporosis: insights afforded by epidemiologyBone17505S11S8573428
   PubMed Web of Science ®Google Scholar
• RiggsBLParfittAM2005Drugs used to treat osteoporosis: the critical need for a uniform nomenclature based on their action on bone remodelingJ Bone Miner Res201778415647810
   PubMed Web of Science ®Google Scholar
• RittmasterRSBologneseMEttingerMP2000Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronateJ Clin Endocrinol Metab8521293410852440
   PubMed Web of Science ®Google Scholar
• RosenCJ2003The cellular and clinical parameters of anabolic therapy for osteoporosisCrit Rev Eukaryot Gene Expr13253812839095
   PubMed Web of Science ®Google Scholar
• RosenHN2006Epidemiology and causes of osteoporosis [online]. In: UpToDate, Rose BD (ed). Accessed 20 November 2006. URL: http://patients.uptodate.com/topic.asp?file=minmetab/15864
   Google Scholar
• SchneiderELGuralnikJM1990The aging of America. Impact on health care costsJAMA2632335402109105
   PubMed Web of Science ®Google Scholar
• SelyeH1932On the stimulation of new bone-formation with parathyroid extract, irradiated ergosterolEndocrinology1654758
   Google Scholar
• ShraderSPRagucciKR2005Parathyroid hormone (1–84) and treatment of osteoporosisAnn Pharmacother3915111616076911
   PubMed Web of Science ®Google Scholar
• SilvermanSLMillerPDMathisenA2006Effect of parathyroid hormone (1–84) in reducing new vertebral fractures regardless of baseline vertebral fracture status in patients with a wide range of clinical risk factorsJ Bone Miner Res21Suppl 1S173
   Google Scholar
• TamCSHeerscheJNMurrayTM1982Parathyroid hormone stimulates the bone apposition rate independently of its resorptive action: differential effects of intermittent and continuous administrationEndocrinology110506127056211
   PubMed Web of Science ®Google Scholar
• WhiteHAhmadA2005PREOS NPS (Allelix/Nycomed)Curr Opin Investig Drugs6105766
   Google Scholar